 |
answer text |
<p>Regular clinical reviews of patients with severe and moderate haemophilia and access
to physiotherapy services are specified within the service specification for haemophilia
which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf"
target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In
addition, the Haemophilia Quality Dashboard has a metric specifically in relation
to the proportion of severe Haemophilia patients who have had an annual review. Where
local commissioning teams are made aware that haemophilia patients do not have access
to appropriate care then local action plans will be agreed to rectify this.</p><p>The
service specification for haemophilia currently does not require that haemophilia
patients receive tailored dosing of treatment. However, commissioners consider that
this would represent good practice. NHS England has supported clinical teams to provide
tailored dosing, within the parameters of the agreed commissioning criteria and guidelines,
by making a wide range of products available for reimbursement.</p><p>To date, all
licensed and currently marketed products for haemophilia are available for reimbursement.
Some products have been limited to Haemophilia Comprehensive Care Centres due to specific
requirements for supporting services and expertise (these are products for patients
with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to
be engaged in the management of their condition. NHS England, in conjunction with
the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that
tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence
that indicates, but does not confirm, that patients who use Haemtrack have better
clinical outcomes than patients who do not. NHS England supports UKHCDO via the National
Haemophilia Database to provide further data and evidence demonstrating the value
and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national
framework agreements in place that provide access to recombinant factor VIII (rFVIII)
haemophilia products. The one licensed Extended Half Life-Factor VIII product available
in the UK has been funded since September 2016 and a significant number of patients
are now treated with this product. NHS England and other UK Health Commissioners work
closely with clinicians and patient representatives to ensure that the frameworks
continue to meet clinical need whilst delivering good value to the National Health
Service.</p>
|
|
